EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer
Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favourable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited comparative data regarding the EGFR GCN in primary colorectal cancer tumours and corresponding metastases or the effect of anti-EGFR antibody treatment on EGFR GCN in recurrent disease. Additionally, little is known about the potential EGFR GCN changes during anti-EGFR therapy in comparison to other treatment regimens.
Source: Human Pathology - Category: Pathology Authors: Eva-Maria Birkman, Tuulia Avoranta, Annika Ålgars, Eija Korkeila, Minnamaija Lintunen, Laura Lahtinen, Teijo Kuopio, Raija Ristamäki, Olli Carpén, Jari Sundström Tags: Original contribution Source Type: research